Loading…
Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach
Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain...
Saved in:
Published in: | Pharmacognosy Magazine 2021-04, Vol.17 (74), p.268-274 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3 |
container_end_page | 274 |
container_issue | 74 |
container_start_page | 268 |
container_title | Pharmacognosy Magazine |
container_volume | 17 |
creator | Yun, Debo Yang, Yujiao Shang, Bin Dong, Heng Luo, Bo Alahmadi, Tahani Luo, Qing |
description | Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments. |
doi_str_mv | 10.4103/pm.pm_261_20 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2553415866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669072185</galeid><sourcerecordid>A669072185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</originalsourceid><addsrcrecordid>eNptkW9r2zAQxs1YYV27d_sAgr2dE0mWZWUvBqF0ayFspbSvxVk-J2psyZPshnyPfeApyf4wKAKdOH7P6e6eLHvP6EwwWsyHfjb0mkumOX2VndNFJXNBJX99fBc54wv5Jnsb4xOlpWK0Os9-LscR3QSj9Y74lmxtQOc7Yl3bQd8f89Y1k8GG1Htio9lgb8084IChneJBZjBgHeAogmCOpeIY_BbJswXysLoXc_JtdX9XkGjXDjrr1mSAcbOD_SeydEmXwGdPYBiCB7O5zM5a6CK--x0vsscv1w9XN_nq-9fbq-UqN7ziY17xsuEVggRVgKoEU0grUTay5G2NpjEoTVUw1QiaLiZqIbkBUGUtF6qp2-Ii-3Cqm779MWEc9ZOfQmowal6WhWClkvIftYYOdZrRjwFMn1ahl1IuaMWZKhM1e4FKpznsyztsbcr_J_h4EpjgYwzY6iHYHsJeM6oPdurk5V87E_75hO98N2KI227aYdA9Nlvndy9qUlD6j7_FL39iqs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553415866</pqid></control><display><type>article</type><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><source>Publicly Available Content Database</source><source>Alma/SFX Local Collection</source><creator>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</creator><creatorcontrib>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</creatorcontrib><description>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</description><identifier>ISSN: 0973-1296</identifier><identifier>EISSN: 0976-4062</identifier><identifier>DOI: 10.4103/pm.pm_261_20</identifier><language>eng</language><publisher>London: Wolters Kluwer India Pvt. Ltd</publisher><subject>Brain ; Inflammation ; Injuries ; Neurons ; Tumor necrosis factor-TNF</subject><ispartof>Pharmacognosy Magazine, 2021-04, Vol.17 (74), p.268-274</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2553415866?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Yun, Debo</creatorcontrib><creatorcontrib>Yang, Yujiao</creatorcontrib><creatorcontrib>Shang, Bin</creatorcontrib><creatorcontrib>Dong, Heng</creatorcontrib><creatorcontrib>Luo, Bo</creatorcontrib><creatorcontrib>Alahmadi, Tahani</creatorcontrib><creatorcontrib>Luo, Qing</creatorcontrib><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><title>Pharmacognosy Magazine</title><description>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</description><subject>Brain</subject><subject>Inflammation</subject><subject>Injuries</subject><subject>Neurons</subject><subject>Tumor necrosis factor-TNF</subject><issn>0973-1296</issn><issn>0976-4062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkW9r2zAQxs1YYV27d_sAgr2dE0mWZWUvBqF0ayFspbSvxVk-J2psyZPshnyPfeApyf4wKAKdOH7P6e6eLHvP6EwwWsyHfjb0mkumOX2VndNFJXNBJX99fBc54wv5Jnsb4xOlpWK0Os9-LscR3QSj9Y74lmxtQOc7Yl3bQd8f89Y1k8GG1Htio9lgb8084IChneJBZjBgHeAogmCOpeIY_BbJswXysLoXc_JtdX9XkGjXDjrr1mSAcbOD_SeydEmXwGdPYBiCB7O5zM5a6CK--x0vsscv1w9XN_nq-9fbq-UqN7ziY17xsuEVggRVgKoEU0grUTay5G2NpjEoTVUw1QiaLiZqIbkBUGUtF6qp2-Ii-3Cqm779MWEc9ZOfQmowal6WhWClkvIftYYOdZrRjwFMn1ahl1IuaMWZKhM1e4FKpznsyztsbcr_J_h4EpjgYwzY6iHYHsJeM6oPdurk5V87E_75hO98N2KI227aYdA9Nlvndy9qUlD6j7_FL39iqs4</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Yun, Debo</creator><creator>Yang, Yujiao</creator><creator>Shang, Bin</creator><creator>Dong, Heng</creator><creator>Luo, Bo</creator><creator>Alahmadi, Tahani</creator><creator>Luo, Qing</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20210401</creationdate><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><author>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Brain</topic><topic>Inflammation</topic><topic>Injuries</topic><topic>Neurons</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yun, Debo</creatorcontrib><creatorcontrib>Yang, Yujiao</creatorcontrib><creatorcontrib>Shang, Bin</creatorcontrib><creatorcontrib>Dong, Heng</creatorcontrib><creatorcontrib>Luo, Bo</creatorcontrib><creatorcontrib>Alahmadi, Tahani</creatorcontrib><creatorcontrib>Luo, Qing</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Pharmacognosy Magazine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yun, Debo</au><au>Yang, Yujiao</au><au>Shang, Bin</au><au>Dong, Heng</au><au>Luo, Bo</au><au>Alahmadi, Tahani</au><au>Luo, Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</atitle><jtitle>Pharmacognosy Magazine</jtitle><date>2021-04-01</date><risdate>2021</risdate><volume>17</volume><issue>74</issue><spage>268</spage><epage>274</epage><pages>268-274</pages><issn>0973-1296</issn><eissn>0976-4062</eissn><abstract>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</abstract><cop>London</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/pm.pm_261_20</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0973-1296 |
ispartof | Pharmacognosy Magazine, 2021-04, Vol.17 (74), p.268-274 |
issn | 0973-1296 0976-4062 |
language | eng |
recordid | cdi_proquest_journals_2553415866 |
source | Publicly Available Content Database; Alma/SFX Local Collection |
subjects | Brain Inflammation Injuries Neurons Tumor necrosis factor-TNF |
title | Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Attenuation%20of%20kirenol%20inflammationinduced%20by%20ischemic/reperfusion%20cerebral%20infarction%20stroke%20via%20TLR4/%20NLRP3%20signaling%20pathway:%20An%20in%20vivo%20approach&rft.jtitle=Pharmacognosy%20Magazine&rft.au=Yun,%20Debo&rft.date=2021-04-01&rft.volume=17&rft.issue=74&rft.spage=268&rft.epage=274&rft.pages=268-274&rft.issn=0973-1296&rft.eissn=0976-4062&rft_id=info:doi/10.4103/pm.pm_261_20&rft_dat=%3Cgale_proqu%3EA669072185%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2553415866&rft_id=info:pmid/&rft_galeid=A669072185&rfr_iscdi=true |